Case Report. 15th June Carolina Ourique Luciana Frade Daniela Alves

Similar documents
Disclosures. Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies. None

Test Result Reference Range Flag

Scleritis LEN V KOH OD

9/13/2015. Nothing to disclose

Tables of Normal Values (As of February 2005)

Case report Fever in a patient with ANCA-associated vasculitis

Is it Autoimmune or NOT! Presented to AONP! October 2015!

SHO Teaching. Dr. Amir Bhanji Consultant Nephrologist, Q.A hospital, Portsmouth

monoclonal gammopathy of undetermin Citation Rheumatology international, 33(1),

Case Presentation. Rafid Asfar, MD

A 48-Year Old Woman with Recurrent Venous Thromboembolism and Pulmonary Artery Aneurysm

Vasculitis local: systemic

LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS LUPUS 101 SLE SUBSETS AUTOIMMUNE DISEASE 11/4/2013 HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS

RAPIDLY FAILING KIDNEYS. Dr Paul Johny 2 nd yr DNB Medicine Resident

Vasculitis. Edward Dwyer, M.D. Division of Rheumatology. Vasculitis

Specific Panels. Celiac disease panel. Pancreas Panel:

CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation)

Case Presentation VASCULITIS. Case Presentation. Case Presentation. Vasculitis

REGISTRATION FORM 1 / 2

Fever in Lupus. 21 st April 2014

VASCULITIS. Case Presentation. Case Presentation

2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.

Systemic examination

PAEDIATRIC VASCULITIS

Fever of unknown origin

The Sequential Development of Antiglomerular Basement Membrane Nephritis and Myeloperoxidase-antineutrophil Cytoplasmic Antibody-associated Vasculitis

One problem above the diaphragm and one problem below the diaphragm

Clinical & Laboratory Assessment

Vasculitis local: systemic

Case report 24 th Summer School of Internal Medicine 2015

Immune-mediated lung disease. Ian Sabroe

CHECK LIST FORM-SCREENING

ESIM Winter School 2014 Case Presentation

CHECK LIST FORM-SCREENING

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES ALDO E CELE DACCO

INTRODUCTION. nephropathy, however, usually presents as membranoproliferative

AKI Case study -Vasculitis. Sarah Mackie Renal Practice Development Nurse King s College Hospital - London

NEW RCPCH REFERENCE RANGES-

Mohammad Reza Shakibi M.D Kerman university of medical sciences (KMU) Shafa Hospital, Rheumatology ward

Management of Acute Vasculitis. CMT teaching 3 rd June 2015 Caroline Wroe

AAM Case Discussion Guide Key Learning Objectives

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

Supplemental Figures and Legends

Pulmonary Embolism Is it the Greatest Danger in Deep Vein Thrombosis?

a mimicker of Wegener s Granulomatosis

Efficacy and safety of brexpiprazole for the treatment of acute. schizophrenia: a 6-week, randomized, double-blind, placebocontrolled

SydPath Reference Intervals for Clinical Trials (Contract Pathology Unit) Unauthorised Copy

Immunoadsorption in Lupus

Dr Kirsten Herbert. Dr Melita Kenealy. MBBS(Hons) FRCPA FRACP. Common Blood Tests

Atypical Subacute Recurrence of Catastrophic Antiphospholipid Syndrome in a Japanese Female Patient

Case report. Open Access. Abstract

Clinician Blood Panel Results

Laboratory Testing for the Primary Care Optometrist

TOCILIZUMAB FOR DIFFICULT TO TREAT IDIOPATHIC RETROPERITONEAL FIBROSIS. A PILOT TRIAL

Small Vessel Vasculitis

Case Report Cocaine Induced Vasculitis: Have We Found a Culprit?

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

Epic Labs Orderable As STAT PRIORITY As of 06/22/2016

BC Biomedical Laboratories Adult Reference Ranges

9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Collect and label sample according to standard protocols. Gently invert tube 8-10 times immediately after draw. DO NOT SHAKE. Do not centrifuge.

Undifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD

UKITP INITAL INFORMATION SHEET (2.4)

Management of acute alcoholic hepatitis

DISCUSSION BY: Dr M. R. Shakeebi, MD, Rheumatologist

Clinician Blood Panel Results

Vasculitis and Vasculitides. OMONDI OYOO Physician/Rheumatologist; Senior Lecturer, Department of Medicine University of Nairobi

VASCULITIC SYNDROMES. Howard L. Feinberg, D.O., F.A.C.O.I., F.A.C.R. OPSC 2018

CUTANEOUS VASCULITIS. Katharine Warburton ST6 Dermatology

Platelet and WBC disorders

Tell me more about vasculitis. Lisa Willcocks Consultant in Nephrology and Vasculitis, Addenbrooke s Hospital

NP30179 Eligibility Screening Form (ESF) Version 3.0

THE TIP OF THE ICEBERG SAMER BOLIS, DO PGY-3 LEHIGH VALLEY HEALTH NETWORK, ALLENTOWN PA

1.) 3 yr old FS Siamese cat: 3 day history of lethargy, anorexia. Dyspneic, thin, febrile.

CLIA APPROVED PROFICIENCY TESTING PROGRAMS ACCUTEST, INC. P.O. Box 999 Westford, Massachusetts (800)

NORMAL LABORATORY VALUES FOR CHILDREN

e-figure 1. The design of the study.

VOICE Screening Part 1 Visit. Operational Walkthrough Johannesburg, South Africa November 2008

CIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed:

ERROR CORRECTION FORM

Average adult = 8-10 pints of blood. Functions:

Rapid Laboratories In House Tests

A TRICKY PROBLEM. Presenter-Dr Lakshmi PK

Comparison of VACUETTE Heparin Gel Tubes for Common Chemistry Analytes

Hematology. The Study of blood

Medical Immunology Practice Questions-2016 Autoimmunity + Case Studies

Successful Treatment with Cyclosporin A in Tocilizumab-resistant TAFRO Syndrome

Guidelines for management of stroke in childhood

Hamilton Regional Laboratory Medicine Program

Complete Medical History

Supplementary Figure Legends

The Complete Blood Count

PS + MPs PS - MPs 37% 36% 64% 64%

Chapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89

PULMONARY MEDICINE BOARD REVIEW. Financial Conflicts of Interest. Question #1: Question #1 (Cont.): None. Christopher H. Fanta, M.D.

Chemistry Reference Ranges and Critical Values

Chemistry Reference Ranges and Critical Values

ACCME/Disclosures 4/13/2016. Clinical History

ANCA associated vasculitis in China

Transcription:

Case Report 15th June 2016 Carolina Ourique Luciana Frade Daniela Alves

CASE REPORT Woman 23 year-old Single Profission: Social-cultural animator for children

CASE REPORT PERSONAL MEDICAL HISTORY Smoker (8 cigarretes/day, for 4 years) Menarche: 13 years. Oral contraceptive (progesterone and estrogen). Nulliparous. No other chronic medication

CASE REPORT FAMILIAR MEDICAL HISTORY Irrelevant No autoimune disease, thrombosis events, neoplasic history.

CASE REPORT 10 th NOVEMBER 12 th NOVEMBER Sudden onset of milimetric dark spot in the tip of the nose purplish color Slightly painful ER 2 days of progressive increase in the lesion area, with local paresthesia, pain and cold. Non hemorrhagic or ulcerated. Without exudate. No fever. Without other symptoms.

CASE REPORT MEDICAL EXAMINATION IN ER: Hemodynamic stability. No fever. Anterior Rhinoscopy: Poor perfusion lesion extending to bilateral anterior nasal vestibule and septum. REMAINING CLINICAL EXAMINATION UNREMARKABLE: No other poor perfusion areas. No livedo reticularis, other cutaneous lesions or arthritis signs. No visible cartilage deformity. No ocular abnormalities NASAL BIOPSY Normal cardiovascular, respiratory and neurological examination. No palpable lymphadenopathy, or hepatosplenomegaly.

CASE REPORT Analysis in ER RESULT REFERENCE VALUE/ UNIT Hemoglobin 11.5 12-16 g/dl Hematocrit 36.8 37-49 % Mean Corpuscular Volume 87.0 87-103 fl Mean Cell Hb concentration 33.0 28-36 g/dl Leukocytes 7.86 4-11 x10 9 /L Neutrophils 64.9 53.8-69.8 % Eosinophils 0.3 0.6-4.6% Basophils 0.3 0-1.5% Lymphocytes 27.1 22.6-36.6% Monocytes 6.6 4.7-8.7% Platelets 211 150-400 x10 9 /L

CASE REPORT RESULT REFERENCE VALUE/ UNIT Urea 20 10-50 mg/dl Creatinine 0.75 0.51-0.95 mg/dl AST Aspartate Aminotransferase ALT Alanine Aminotransferase CK Creatinina kinase 22 10-31 U/L 17 10-31 U/L 11 10-149 U/L Myoglobin 12.4 <146.9 ng/ml CRP C-Reactive Protein 178.1 <3 mg/l Glucose 83 75-110 mg/dl aptt 29.7 24.5-36.5 sec PT 12.6 10.2-13.9 sec Fibrinogen 645 190-400 mg/dl Urinary sediment analysis Normal

Question 1. Which are the main diagnostic hypothesis?

Question 1. A) Trauma, infection or cocaine abuse. B) Vasculitis. C) Relapsing Polychondritis. D) Thinking nothing by now.

CASE REPORT No history of Nose manipulation/ trauma. Cocaine abuse, cosmetic products/ plastic surgery. Recent travels, tuberculosis contact, risk for sexual transmited diseases. Other medication (besides OAC). Autoimmune disease, asthma, rhinosinusitis. Constitutional symptoms.

CASE REPORT 13 th November ADMISSION Day 1

Question 2. Which therapy would you start?

Question 2. A) Sistemic steroids. B) Low molecular weight heparin. C) Empiric antimicrobial therapy. D) A and B options. E) Wait and see.

CASE REPORT Enoxaparin 40 mg SC Methylprednisolone 1 g EV ADMISSION IN INTERNAL MEDICINE DEPARTMENT Nasal Necrosis

Question 3. Which diagnostic studies would you demand first?

Question 3. A) Lung and upper airway imaging study. B) Viral markers (HCV, HBV and HIV) and syphilis test. C) Autoimmune study, serum complement levels and prothrombotic study. D) All options above.

CASE REPORT RESULT HIV (1 & 2) HCV antibody HBs antigen, HBc antibody TPPA/ TP CMV, EBV, Parvovirus B19 Negative Negative Negative Negative Negative for acute infection

CASE REPORT CERVICAL AND THORACIC CT - No changes in nasopharynx, oropharynx or larynx. - No changes in submandibular, parotid and thyroid glands. - Homogeneous pulmonary parenchyma, without signs of interstitium disease. -No pleural or pericardial effusion. -No cervical, axilary, hilar and mediastinal lymphadenopathy.

CASE REPORT AUTOIMMUNE STUDY Antinuclear antibody Anti-DsDNA antibody ANCA (PR3, MPO) Antineutrophil cytoplasmic antibodies RESULT Rheumatoid Factor 594 (<30 UL/mL) COMPLEMENT RESULT C4 7 (12-36 mg/dl) CH50 40 63-145 UA Anti-ENA (anti-jo 1, anti-rnp, anti-scl70, anti-sm, anti-ssa, anti-ssb) Anticardiolipin antibodies Antibodies to Beta-2-GP-1 Lupus Anticoagulant Serum crioglobulins RESULT PROTHROMBOTIC STUDY RESULT C, S proteins Normal Factor V mutation Prothrombine mutation gene AT-III Antithrombin III Negative Normal Homozigotic Normal

CASE REPORT ESR Erythrocyte Sedimentation Rate CRP C-Reactive Protein RESULT REFERENCE VALUE/ UNIT 83 0-25 mm/1 st h 134.8 <3 mg/l

CASE REPORT NEGATIVE HISTOCHEMICAL STUDY FOR MICROORGANISMS SEARCH IN BIOPSY.

CLINICAL PROGRESSION TIME ADMISSION THERAPY DAY 2 3 rd Pulse MethylPDN + LMWH full dose DAY 3 PDN 50 mg + LMWH full dose

Question 4. Would you keep previous therapy (sistemic steroids and LMWH in full dose)?

Question 4. A) Yes, keep therapy. B) No, start immediatly agressive immunosuppression with cyclophosphamide/ rituximab. C) Stop steroids and begin dapsone. D) Still have no idea.

Vessels filled with homogeneous, eosinophilic material. No evidence of vasculitis.

epidermis Fibrin material in the lumen of a small vein Scattered perivascular infiltrate Vessel affected in the papillary dermis

CASE REPORT AUTOIMMUNE STUDY Antibuclear antibody RESULT Negative Anti-DsDNA antibody <10 ANCA (PR3, MPO) Antineutrophil cytoplasmic antibodies <20 Rheumatoid Factor 594 (<30 UL/mL) Anti-ENA (anti-jo 1, anti-rnp, anti-scl70, anti-sm, anti-ssa, anti- SSb) Anticardiolipin antibodies Negative Negative Antibodies to Beta-2-GP-1 Lupus Anticoagulant Negative Positive Serum crioglobulins RESULT Positive

LESS LIKELY DIAGNOSIS TRAUMA COCAIN ABUSE COSMETIC PRODUCTS INFECTION -No immunossupression. -No travel history. No risk contact for tuberculosis/ sífilis. -No microorganisms were seen in biopsy. - HIV, HCV and HBV were excluded. VASCULITIS - ANCA negative. - No pulmonar, upper airway or renal involvement. -No eosinophilia. LYMPHOPROLIFERATIVE DISORDERS -Absence lymphadenophathy, hemogram abnormalities, hepatosplenomegaly. - Absence of fever, important constitutional symptoms, low LDH. RELAPSING POLYCHONDRITIS - No involvement of other cartilaginous areas. -No ocular inflammation or vestibulo/cochlear dysfuntion. -No eosinophilia or ANCA positive. -CH50 and C4 are usually normal.

Question 5. What is the final diagnosis?

Question 5. A) Cryoglobulinemia. B) Antiphospholipid syndrome. C) Both.

Day 6 Day 8 Day 9 Day 10 Day 13 Day 16

Question 6. What should be the treatment after discharge?

Question 6. A) Sistemic steroids only. B) Anticoagulants only. C) Rituximab. D) A and B options.

1 YEAR HAS PASSED Assintomatic Tapering oral steroids- progressive reduction of PDN to 10 mg/day. Anticoagulation 2013 2014 NOVEMBER JANUARY MARCH APRIL MAY JULY Rheumatoid Factor (UL/mL) 594 399 277 186 164 159 apl / AL negative

PORTO LISBON CASTELO BRANCO AZORES Thank you for listening!